PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29187479-9 2017 In the group of patients who received adjuvant chemotherapy based on platinum derivatives in combination with paclitaxel or gemcitabine, we found shorter DFI (p=0.0473) and OS (p=0.0053) in those with high expression of TS. Platinum 69-77 thymidylate synthetase Homo sapiens 220-222 31561530-3 2019 In the effort to identify anti-TS drugs with new modes of action and able to overcome platinum drug resistance in ovarian cancer, octapeptides with a new allosteric inhibition mechanism were identified as cancer cell growth inhibitors that do not cause TS overexpression. Platinum 86-94 thymidylate synthetase Homo sapiens 31-33 29861877-5 2018 Contrasting results, however, have been reported on the capability of variants of other genes as MTHFR, TYMS, ERCC1, XRCC1, GSTP1, CYP3A4/3A5 and ABCB1, in predicting either therapy efficacy or toxicity in patients undergoing treatment with pyrimidine antimetabolites, platinum derivatives, irinotecan and taxanes. Platinum 269-277 thymidylate synthetase Homo sapiens 104-108 25573098-12 2015 Expression of ERCC1, TYMS, TUBB3, non-muscle myosin II, myoglobin and MyoD1 was also associated with decreased survival rates of patients with lung adenocarcinoma treated with platinum-based chemotherapy. Platinum 176-184 thymidylate synthetase Homo sapiens 21-25 26740498-0 2016 Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. Platinum 17-25 thymidylate synthetase Homo sapiens 122-126 25246386-0 2014 Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Platinum 80-88 thymidylate synthetase Homo sapiens 20-22 26638920-5 2015 Finally, thymidylate synthase protein cutoffs may predict mesothelioma response to the association of pemetrexed with a platinum derivative. Platinum 120-128 thymidylate synthetase Homo sapiens 9-29 24554028-0 2014 Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Platinum 134-142 thymidylate synthetase Homo sapiens 0-20 24554028-2 2014 This study was conducted to evaluate the influence of TYMS polymorphisms on the survival of Portuguese patients with advanced non-small cell lung cancer (NSCLC) undergoing platinum-based chemotherapy. Platinum 172-180 thymidylate synthetase Homo sapiens 54-58 24554028-8 2014 According to our results, the TYMS polymorphisms may be useful tools to predict which advanced NSCLC patients could benefit more from platinum-based chemotherapy regimens. Platinum 134-142 thymidylate synthetase Homo sapiens 30-34 23645741-4 2013 Moreover, TYMS copy number was significantly lower in clinical NSCLC samples responsive to treatment with pemetrexed combined with platinum drugs (p=0.0067). Platinum 131-139 thymidylate synthetase Homo sapiens 10-14 23645741-5 2013 Furthermore, the decrease in the baseline CT size measurement of pemetrexed combined with platinum drug treatment correlated significantly with TYMS copy number (r=0.7967, p=0.0011). Platinum 90-98 thymidylate synthetase Homo sapiens 144-148 22866924-17 2012 With this approach, NSCLC patients with aberrant intratumoral TYMS expression will probably fare better with platinum-based treatments. Platinum 109-117 thymidylate synthetase Homo sapiens 62-66 34141464-9 2021 The genes interacted with TYMS and BCL2L1 were linked to functional networks involving pathway of apoptosis, apoptosis-multiple species, colorectal cancer, platinum drug resistance and p53 signaling pathway. Platinum 156-164 thymidylate synthetase Homo sapiens 26-30 21970874-1 2011 BACKGROUND: Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted. Platinum 113-121 thymidylate synthetase Homo sapiens 64-66 17465714-3 2007 The most recent update regarding gastric cancer pharmacogenetics highlights a prominent role of genetic polymorphisms of thymidylate synthase and glutathione S-transferase in the pharmacological treatment with commonly used drugs, such as 5-fluorouracil and platinum derivatives. Platinum 258-266 thymidylate synthetase Homo sapiens 121-141 35086099-0 2022 Polymorphism in Thymidylate Synthase Gene Predicts Survival and Toxicity in North Indian Lung Cancer Patients Undergoing Platinum-Based Doublet Chemotherapy. Platinum 121-129 thymidylate synthetase Homo sapiens 16-36 35086099-2 2022 Thymidylate synthase (TS) is an important drug target for platinum-based doublet chemotherapy as it is the only de novo source of thymidylate production in the cell. Platinum 58-66 thymidylate synthetase Homo sapiens 0-20 35086099-2 2022 Thymidylate synthase (TS) is an important drug target for platinum-based doublet chemotherapy as it is the only de novo source of thymidylate production in the cell. Platinum 58-66 thymidylate synthetase Homo sapiens 22-24 35086099-11 2022 Furthermore, TS polymorphisms may influence the onset of platinum-related toxicity, such as hematological and gastrointestinal toxicity. Platinum 57-65 thymidylate synthetase Homo sapiens 13-15